FEZ2

Across TCGA pan-cancer cohorts, FEZ2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FEZ2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FEZ2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FEZ2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where FEZ2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.795	0.257	<.001	20	view →
LSCC	DFS	Quartile	III,IV	0.563	0.979	.036	12	view →
HNSC	OS	Quartile	III,IV	0.969	0.743	.018	9	view →
CCRCC	OS	Median	All	1.000	0.911	.023	4	view →
GBM	DFS	Median	All	0.213	0.409	.012	4	view →
LUAD	OS	Median	All	0.767	0.895	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FEZ2–PDAC (DFS)

Open the PDAC breakdown →